Follicular-Phase GnRH Agonist Protocol Is Another Choice for Polycystic Ovary Syndrome Patients With Lower LH/FSH and Lower AMH Levels Without Increasing Severe OHSS Risk

Rui Gao, Xin Liao, Wanrong Huang, Rujun Zeng, Lang Qin, Peng BaiFrontiers in Endocrinology 2022 · DOI

Abstract

The limited evidence from this study indicates that in PCOS patients with lower bLH/FSH levels (<1.33) and lower serum AMH levels (≤3.4 ng/ml), a follicular-phase GnRH agonist protocol may be another choice that does not increase the risk of severe OHSS.

Introduction

Polycystic Ovary Syndrome (PCOS) is a primary cause of female infertility, often requiring Controlled Ovarian Stimulation (COS) for In Vitro Fertilization (IVF). However, PCOS patients are typically "high responders," making them highly susceptible to Ovarian Hyperstimulation Syndrome (OHSS)—a potentially life-threatening complication.

To minimize this risk, the GnRH antagonist protocol is widely considered the gold standard for PCOS patients. However, some clinical evidence suggests that the follicular-phase GnRH agonist protocol might offer superior clinical pregnancy and live birth rates by improving endometrial receptivity. This study investigates whether a "safe zone" exists where the agonist protocol can be utilized without increasing the risk of severe OHSS.

Methods

Researchers at West China Second University Hospital conducted a retrospective cohort study of 364 PCOS patients undergoing their first IVF/ICSI cycle. The cohort was divided into two groups:

  • Group 1 (n=295): Fixed GnRH antagonist protocol.
  • Group 2 (n=69): Follicular-phase GnRH agonist protocol.

The study compared baseline characteristics, stimulation metrics, and clinical outcomes, with a specific focus on identifying biomarkers—Anti-Müllerian Hormone (AMH) and baseline LH/FSH ratio—that could predict safety.

Clinical Outcomes and OHSS Risk

Initial analysis of the total cohort revealed that the follicular-phase GnRH agonist protocol was associated with a significantly higher incidence of severe OHSS compared to the antagonist protocol (11.6% vs. 3.7%, p=0.008). Additionally, the agonist group required longer stimulation durations and higher total doses of gonadotropins.

Table 2: Stimulation and clinical outcomes between the two groups.

Despite the increased OHSS risk in the general PCOS population, pregnancy outcomes remained comparable between the two groups. The clinical pregnancy rate for the agonist group was 62.5%, compared to 54.3% in the antagonist group, though this difference did not reach statistical significance.

Identifying the "Safe Zone"

The core of the study involved a subgroup analysis to determine if specific hormonal baselines could mitigate the risks associated with the agonist protocol. The researchers identified two critical thresholds: a baseline LH/FSH ratio (bLH/FSH) of 1.33 and an AMH level of 3.4 ng/ml.

Table 3: Subgroup analysis of severe OHSS risk based on bLH/FSH and AMH levels.

As shown in the subgroup analysis, for patients with bLH/FSH < 1.33 or AMH ≤ 3.4 ng/ml, there was no statistically significant difference in the risk of severe OHSS between the two protocols. Conversely, patients exceeding these thresholds saw a dramatic increase in OHSS risk when using the agonist protocol (e.g., 21.9% vs 5.2% for bLH/FSH ≥ 1.33).

Discussion and Conclusion

The findings support a shift toward personalized medicine in fertility treatments. The physiological basis for these results may lie in the "Two-Cell Theory." In the antagonist protocol, endogenous LH is not fully suppressed early on, which may naturally inhibit overstimulation. In the agonist protocol, pituitary downregulation suppresses LH; for patients with already low baseline LH and AMH, the mechanism for "overreaction" is less likely to be triggered.

While the study is limited by its retrospective design and small sample size in the agonist group, it suggests that the follicular-phase GnRH agonist protocol is a viable and safe alternative for PCOS patients with lower baseline hormone markers. Future large-scale prospective studies are needed to validate these specific cutoff values before broad clinical implementation.

Summary updated

Abstract

The limited evidence from this study indicates that in PCOS patients with lower bLH/FSH levels (<1.33) and lower serum AMH levels (≤3.4 ng/ml), a follicular-phase GnRH agonist protocol may be another choice that does not increase the risk of severe OHSS.
BibTeX
@inproceedings{gao2022follicular,
  author = {Rui Gao and Xin Liao and Wanrong Huang and Rujun Zeng and Lang Qin and Peng Bai},
  title = {{Follicular-Phase GnRH Agonist Protocol Is Another Choice for Polycystic Ovary Syndrome Patients With Lower LH/FSH and Lower AMH Levels Without Increasing Severe OHSS Risk}},
  booktitle = {Frontiers in Endocrinology},
  year = {2022},
  doi = {10.3389/fendo.2022.905263},
}
Figure